C07K 14/665
Derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
Official title: derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
C07K14/665 (Derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin) appears on 549 US grants and 403 published applications in this corpus.
Search patents in C07K- Granted patents
- 549
- Published applications
- 403
- Assignees
- 264
- Inventors
- 882
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 5 | 0 |
| 1978 | 42 | 0 |
| 1979 | 9 | 0 |
| 1980 | 14 | 0 |
| 1981 | 22 | 0 |
| 1982 | 20 | 0 |
| 1983 | 14 | 0 |
| 1984 | 17 | 0 |
| 1985 | 9 | 0 |
| 1986 | 8 | 0 |
| 1987 | 7 | 0 |
| 1988 | 3 | 0 |
| 1989 | 6 | 0 |
| 1990 | 4 | 0 |
| 1991 | 5 | 0 |
| 1992 | 7 | 0 |
| 1993 | 5 | 0 |
| 1994 | 9 | 0 |
| 1995 | 6 | 0 |
| 1996 | 7 | 0 |
| 1997 | 15 | 0 |
| 1998 | 19 | 0 |
| 1999 | 12 | 0 |
| 2000 | 9 | 0 |
| 2001 | 11 | 6 |
| 2002 | 5 | 11 |
| 2003 | 12 | 14 |
| 2004 | 10 | 17 |
| 2005 | 9 | 22 |
| 2006 | 10 | 22 |
| 2007 | 10 | 17 |
| 2008 | 7 | 30 |
| 2009 | 11 | 20 |
| 2010 | 12 | 19 |
| 2011 | 18 | 13 |
| 2012 | 5 | 29 |
| 2013 | 22 | 16 |
| 2014 | 16 | 20 |
| 2015 | 14 | 14 |
| 2016 | 21 | 20 |
| 2017 | 15 | 21 |
| 2018 | 7 | 19 |
| 2019 | 13 | 12 |
| 2020 | 7 | 11 |
| 2021 | 8 | 11 |
| 2022 | 8 | 13 |
| 2023 | 6 | 3 |
| 2024 | 8 | 7 |
| 2025 | 5 | 6 |
| 2026 | 2 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers16 Jun 2026US 12,655,178 B2Rhythm Pharmaceuticals, Inc.
- Recombinant protein comprising multiple multi-peptide sets, pharmaceutical composition comprising the recombinant protein, and method for preparing the recombinant protein13 Jan 2026US 12,522,642 B2
- Conjugation of MCR1 ligand with cytotoxic drugs for treating skin cancer14 Oct 2025US 12,440,570 B2Arizona Board of Regents on Behalf of the University of Arizona
- Amino diacids containing peptide modifiers14 Oct 2025US 12,441,760 B2Chemical & Biopharmaceutical Laboratories of Patras S.A.
- Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages20 May 2025US 12,303,555 B2Nanyang Technological University
- Methods and compositions for displaying peptide libraries8 Oct 2026US 2026/0308224 A1Board of Regents, The University of Texas System
- Melanocortin receptor ligands modified with hydantoin1 Oct 2026US 2026/0297130 A1Ipsen Pharma S.A.S.
- Engineered nucleic acids and methods of use thereof6 Aug 2026US 2026/0224664 A1Moderna TX, Inc.
- Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers11 Jun 2026US 2026/0159543 A1Rhythm Pharmaceuticals, Inc.
- Compositions for the treatment of disease4 Jun 2026US 2026/0151434 A1SightStream Biotherapeutics, Inc.
Most cited
By later US patents
- Engineered nucleic acids and methods of use thereof372US 8,822,663 B2Moderna Therapeutics, Inc. · 2014
- Chimeric peptides for neuropeptide delivery through the blood-brain barrier238US 4,801,575 AThe Regents of the University of California · 1989
- DNA sequencing by mass spectrometry via exonuclease degradation235US 6,074,823 ASequenom, Inc. · 2000
- Chimeric peptides for neuropeptide delivery through the blood-brain barrier215US 4,902,505 AAlkermes, Inc. · 1990
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006